Ferroptosis regulator as a novel therapeutic target for STK11/KEAP1 co-mutant lung adenocarcinoma

Bookmark and Share
Published: 20 Jan 2021
Views: 938
Rating:
Save
Dr Triparna Sen - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Triparna Sen speaks to ecancer about her recent study regarding ferroptosis regulator as a novel therapeutic target for STK11/KEAP1 co-mutant lung adenocarcinoma.

In this interview, she talks about what her study was about and what were the initial findings that led to the further development of the study.

She talks about the concept of ferroptosis and explains in detail what it entails. She refers to her paper which explores this concept.

In the end, she explains STK11 and KEAP1 mutations which can be observed in some types of lung cancer and the therapeutic options available for them.

For information regarding the related paper see here.